India's Exports of Active Pharma Ingredients at Rs 41,500 Cr Surpassed Imports in FY25

Why It Matters

The shift to net API exports reduces India’s reliance on Chinese supplies and strengthens its position in the global pharma supply chain, boosting trade balance and strategic self‑reliance.

Key Takeaways

• API exports reached Rs 41,500 crore in FY25.
• Imports fell short at Rs 39,215 crore.
• China supplies 74% of API imports.
• PLI scheme allocates Rs 6,940 crore incentives.
• Domestic capacity added 56,800 tonnes annually.

Pulse Analysis

India’s active pharmaceutical ingredient (API) market posted a landmark trade balance in FY25, with exports climbing to roughly Rs 41.5 billion while imports lagged at Rs 39.2 billion. The surplus marks the first time the sector has out‑exported its imports, signaling a maturing domestic manufacturing base. Exports grew 8% year‑on‑year, outpacing the 5% rise in imports, and the surplus also improves the current account, contributing to macroeconomic stability. China still supplied 74% of API imports, underscoring the need for diversification.

The government’s Production Linked Incentive (PLI) scheme underpins this turnaround, allocating Rs 6.94 billion to spur domestic production of key starting materials, drug intermediates and APIs. Since its launch, the programme has added about 56,800 tonnes of annual capacity across 28 critical products, generated Rs 2.72 billion in sales and created nearly 5,000 jobs. Complementary measures such as anti‑dumping duties and a minimum import price aim to protect nascent manufacturers and curb excessive reliance on Chinese supplies. Exports under the scheme already reached Rs 528 crore, demonstrating early traction, and the scheme’s funding is expected to double by FY27, accelerating scale‑up.

By narrowing the import‑export gap, India positions itself as a credible alternative source for global pharma manufacturers seeking supply‑chain resilience. The reduced dependence on China not only mitigates geopolitical risk but also strengthens India’s bargaining power in international trade negotiations. International firms are eyeing joint ventures to tap the expanding domestic capacity. If export momentum sustains, India could capture a larger share of the $200 billion global API market, reinforcing the country’s ambition to become a self‑reliant pharma hub.